Ultrasonographic Response to Polarized Light Therapy in the Treatment of Atopic Dermatitis
Study Details
Study Description
Brief Summary
Non-atopic dermatitis (NAD) or eczema is a common inflammatory condition; potentially debilitating that can compromise quality of life. It is usually seen in childhood, but can onset within or persist into adulthood.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Polarized ultraviolet-free polychromatic light is used as therapeutic option for the treatment of wound healing and dermatological conditions.
40 male patients who had atopic dermatitis in the chronic stage, they were complaining from itching, inflammation and skin thickness in the arm, wrist, hand and leg will participate in this study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| polarized light group group A (20 patients) will receive Polarized light therapy |
Device: polarized light
A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute
|
| topical corticosteroid group group B (20 patients) will receive topical corticosteroid therapy |
Drug: Topical corticosteroid ointment
corticosteroid 1 %.
|
Outcome Measures
Primary Outcome Measures
- Ultrasonography [1-2 months]
Ultrasound imaging system used to measure the thickness of the skin at the site of scale for both groups
Secondary Outcome Measures
- SCORAD Score [1-2 months]
The SCORAD (Index) is the best validated scoring system in atopic dermatitis, To measure the extent of AD, the rule of nines is applied on a front/back drawing of the patient's inflammatory lesions. The extent can be graded from 0 to 100. The intensity part of the SCORAD consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness. Each item can be graded on a scale from 0 to 3. The subjective items include daily pruritus and sleeplessness. The SCORAD Index formula is: A/5 + 7B/2 + C. In this formula A is defined as the extent (0-100), B is defined as the intensity (0-18) and C is defined as the subjective symptoms (0-20). The maximal score of the SCORAD Index is 103. The objective SCORAD consist of the extent and the intensity items; the formula is A/5 + 7B/2. The maximal objective SCORAD score is 83 (with 10 additional points for severe disfiguring eczema of the face and hands).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
The patients' ages will ranged from 20 to 30 years.
-
The subjects will be males.
-
The duration of disease less than 1 year.
Exclusion Criteria:
-
patients who had skin malignancy in the area to be treated.
-
The patients who had history of diabetes, circulatory or sensory disorders.
-
Patients with acute infection in the area treated.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Ahram Canadian University | Giza | Egypt |
Sponsors and Collaborators
- Ahram Canadian University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AhramCUE